AstraZeneca spinoff Viela Bio has gone public in an offering that involved existing backers buying some $70m worth of stock, and its share price has since risen 21.7%.
Praktikertjänst-backed Aprea Therapeutics has priced its shares at $15 to raise $85m, with stock rising a third to $20.50 on the first day of trading.
The Alexandria Real Estate Equities-backed regenerative medicine developer floated at the bottom of its range while cutting the number of shares.
The Pfizer and Chiesi-backed gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.
Ant Financial and Nikkei will have the chance to exit Chinese media and startup services provider 36Kr, which has filed for a $100m initial public offering in the US.
The GV-backed genomic editing technology developer has filed to raise up to $100m, adding to some $225m of venture funding in under three years.